Author: Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, Boyce LM, Tripathy D
Year: 2017
AGREE II score: Available
Developer organization: Society for Integrative Oncology
Type of cancer: Breast
Patient population: Adult
Location: International
This is a clinical practice guideline for patients with breast cancer. The guideline examines the use of integrative therapies for specific clinical indications during and after breast cancer treatment. The integrative therapies discussed in the guideline address anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 83.3%
Applicability: 60.4%
Stakeholder involvement: 44.4%
Editorial independence: 16.7%
Rigour: 70.8%
Clarity presentation: 91.7%
